マルタ - 英語 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - concentrate for solution for infusion or injection - fludarabine phosphate 25 mg/ml - antineoplastic agents

イスラエル - 英語 - Ministry of Health

salomon,levin & elstein ltd - fludarabine phosphate 50 mg / 2 ml - concentrate for solution for injection / infusion - fludarabine - palliative treatment of patients with cll refractory to other therapy. treatment of less malignant non-hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. fludarabine teva is indicated for the initial treatment of patients with b- cell chronic lymphocytic leukaemia (cll) or after first line therapy, in patients with sufficient bone marrow reserves.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

ebewe pharma ges.m.b.h nfg. kg - fludarabine phosphate - concentrate for soln for inf - 25 micromol

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - bendamustine hydrochloride - powder for concentrate for solution for infusion - 25 milligram(s) - nitrogen mustard analogues; bendamustine - antineoplastic agents, alkylating agents - first-line treatment of chronic lymphocytic leukaemia. indolent non-hodgkin's lymphomas. front line treatment of multiple myeloma

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - bendamustine hydrochloride - powder for concentrate for solution for infusion - 100 milligram(s) - nitrogen mustard analogues; bendamustine - antineoplastic agents, alkylating agents - first-line treatment of chronic lymphocytic leukaemia. indolent non-hodgkin's lymphomas. front line treatment of multiple myeloma.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hospira, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 50 mg in 2 ml - fludarabine phosphate for injection, usp is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate, usp in previously untreated or non-refractory patients with cll have not been established. fludarabine phosphate, usp is contraindicated in those patients who are hypersensitive to this drug or its components.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

fresenius kabi usa, llc - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 25 mg in 1 ml - fludarabine phosphate injection, usp is indicated for the treatment of patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen.  the safety and effectiveness of fludarabine phosphate injection, usp in previously untreated or non-refractory patients with cll have not been established. fludarabine phosphate injection, usp is contraindicated in those patients who are hypersensitive to this drug or its components.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

actavis pharma, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 50 mg in 2 ml - fludarabine phosphate for injection is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate for injection in previously untreated or non-refractory patients with cll have not been established. fludarabine phosphate for injection is contraindicated in those patients who are hypersensitive to this drug or its components.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

sagent pharmaceuticals - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 25 mg in 1 ml - fludarabine phosphate injection is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate injection in previously untreated or non-refractory patients with cll have not been established. none teratogenic effects pregnancy category d [see warnings and precautions (5.6)]. based on its mechanism of action, fludarabine phosphate can cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of fludarabine phosphate in pregnant women. in rats, repeated intravenous doses of fludarabine phosphate at 2.4 times and 7.2 times the recommended human iv dose (25 mg/m2 ) administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (cleft palate, exencephaly, and fetal vertebrae deformities) and decreased f

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - rituximab - solution for injection - 119.66mg/1ml